GW&K Investment Management LLC Boosts Holdings in BioCryst Pharmaceuticals, Inc. $BCRX

Posted by Geri Gentry on Jun 11th, 2026

GW&K Investment Management LLC raised its holdings in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Free Report) by 43.8% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 3,160,924 shares of the biotechnology company’s stock after purchasing an additional 963,159 shares during the quarter. GW&K Investment Management LLC’s holdings in BioCryst Pharmaceuticals were worth $24,655,000 at the end of the most recent reporting period.

Several other hedge funds also recently added to or reduced their stakes in BCRX. Royal Bank of Canada boosted its holdings in BioCryst Pharmaceuticals by 2.4% in the first quarter. Royal Bank of Canada now owns 63,463 shares of the biotechnology company’s stock valued at $476,000 after purchasing an additional 1,458 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in BioCryst Pharmaceuticals by 6.7% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 135,314 shares of the biotechnology company’s stock valued at $1,019,000 after purchasing an additional 8,517 shares during the last quarter. Goldman Sachs Group Inc. boosted its holdings in BioCryst Pharmaceuticals by 49.6% in the first quarter. Goldman Sachs Group Inc. now owns 1,931,934 shares of the biotechnology company’s stock valued at $14,490,000 after purchasing an additional 640,704 shares during the last quarter. Caxton Associates LLP purchased a new stake in BioCryst Pharmaceuticals in the first quarter valued at $314,000. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its holdings in BioCryst Pharmaceuticals by 11.8% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 448,466 shares of the biotechnology company’s stock valued at $3,363,000 after purchasing an additional 47,355 shares during the last quarter. 85.88% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at BioCryst Pharmaceuticals

In related news, insider Alane P. Barnes sold 150,000 shares of the company’s stock in a transaction dated Monday, March 16th. The shares were sold at an average price of $9.15, for a total transaction of $1,372,500.00. Following the completion of the transaction, the insider owned 400,703 shares in the company, valued at $3,666,432.45. This represents a 27.24% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 3.80% of the stock is currently owned by company insiders.

BioCryst Pharmaceuticals Stock Performance

Shares of BioCryst Pharmaceuticals stock opened at $8.19 on Thursday. The firm has a 50-day simple moving average of $8.96 and a two-hundred day simple moving average of $8.10. The company has a market cap of $2.08 billion, a P/E ratio of -4.60 and a beta of 0.57. BioCryst Pharmaceuticals, Inc. has a fifty-two week low of $6.00 and a fifty-two week high of $11.07.

BioCryst Pharmaceuticals (NASDAQ:BCRX – Get Free Report) last released its quarterly earnings results on Wednesday, May 6th. The biotechnology company reported ($2.98) earnings per share for the quarter, missing the consensus estimate of $0.06 by ($3.04). BioCryst Pharmaceuticals had a negative return on equity of 76.36% and a negative net margin of 51.71%.The company had revenue of $156.41 million for the quarter, compared to analyst estimates of $151.12 million. During the same quarter last year, the company earned $0.20 EPS. The firm’s revenue for the quarter was up 7.5% on a year-over-year basis. Equities research analysts forecast that BioCryst Pharmaceuticals, Inc. will post -2.66 EPS for the current year.

Analyst Upgrades and Downgrades

Several research firms have commented on BCRX. Evercore began coverage on shares of BioCryst Pharmaceuticals in a report on Wednesday, February 18th. They issued an “outperform” rating and a $17.00 price target on the stock. Wedbush lowered their price target on shares of BioCryst Pharmaceuticals from $22.00 to $21.00 and set an “outperform” rating on the stock in a report on Thursday, May 7th. Needham & Company LLC lowered their price target on shares of BioCryst Pharmaceuticals from $18.00 to $16.00 and set a “buy” rating on the stock in a report on Wednesday, May 6th. Citizens Jmp upped their price objective on shares of BioCryst Pharmaceuticals from $25.00 to $28.00 and gave the stock a “market outperform” rating in a research report on Thursday, May 7th. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of BioCryst Pharmaceuticals in a research report on Monday, June 1st. Nine research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $20.70.

Get Our Latest Analysis on BCRX

About BioCryst Pharmaceuticals

(Free Report)

BioCryst Pharmaceuticals, Inc is a clinical‐stage biotechnology company headquartered in Durham, North Carolina, that focuses on the discovery and development of novel, oral small‐molecule medicines for rare and serious diseases. Since its founding in 1986, the company has leveraged structure‐based drug design to advance a pipeline of targeted therapeutics designed to address underlying disease mechanisms rather than just treat symptoms.

The company’s first commercial product, Orladeyo (berotralstat), is an oral kallikrein inhibitor approved for the prophylactic treatment of hereditary angioedema (HAE) in both the United States and Europe.